Answers are grounded in this paper and cite their sources.
The recognition of HAT1 in regulating tumor cell proliferation and cancer immunity indicated that HAT1 might be employed as a new diagnostic and prognostic marker and a predictive marker for pancreatic cancer therapy, especially in immune checkpoint blockade therapy. Targeting HAT1 highlights a novel therapeutic approach to overcome immune evasion by tumor cells.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: